Results 21 to 30 of about 21,815 (182)
Diffuse hyperpigmented lichenoid drug eruption secondary to Enzalutamide
Enzalutamide is a potent second-generation androgen receptor (AR) antagonist used to treat metastatic castration resistant prostate carcinoma (mCPRC) and metastatic hormone sensitive prostate carcinoma (mHSPC).
Sabrina Khan +4 more
doaj +1 more source
Resistance of castration‐resistant prostate cancer (CRPC) to enzalutamide and abiraterone involves the expression of constitutively active, truncated androgen receptor (AR) splice variants (AR‐Vs) that lack a C‐terminal ligand‐binding domain (LBD).
Yukiyoshi Hirayama +4 more
doaj +1 more source
Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer.
Despite enzalutamide's efficacy in delaying the progression of metastatic castration-resistant prostate cancer (CRPC), resistance to this anti-androgen inevitably occurs.
Holger H H Erb +12 more
doaj +1 more source
ObjectiveThe androgen receptor-targeting drugs abiraterone acetate and enzalutamide have shown positive results as treatments for metastatic castration-resistant prostate cancer (mCRPC).
ZhenHeng Wei +4 more
doaj +1 more source
Targeting DNMTs to overcome enzalutamide resistance in prostate cancer
Prostate cancer is the second leading cause of cancer death among men in the United States. The androgen receptor (AR) antagonist enzalutamide is a FDA-approved drug for treatment of patients with late-stage prostate cancer and is currently under ...
Liu, Jinpeng +6 more
core +1 more source
Background: Enzalutamide is useful for the treatment of castration-resistant prostate cancer (CRPC). Despite its usefulness, adverse events (AEs) sometimes force patients to discontinue treatment. To maximize patient care, we developed an ambulatory care
Masaki Hirabatake +9 more
doaj +1 more source
CAQ Corner: Basic concepts of transplant immunology
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley +1 more source
Background Emerging data suggest that patients with enzalutamide-treated prostate cancer with increased programmed death-ligand 1 (PD-L1) expression may benefit from anti-PD-L1 treatment. Unfortunately, the Phase III IMbassador250 clinical trial revealed
Bo Chen +9 more
doaj +1 more source
While the overall survival of patients with castration-resistant prostate cancer (CRPC) has been prolonged by enzalutamide, a considerable number of patients suffer from enzalutamide-induced nausea and fatigue.
Takashi Kawahara +3 more
doaj +1 more source
The treatment of metastatic castrate-resistant prostate cancer (mCRPC) has evolved rapidly with the recent approval of a number of treatments and agents, including docetaxel, sipuleucel T, abiraterone, cabazitaxel, and enzalutamide.
Fred Saad
doaj +1 more source

